Ani Pharmaceuticals Inc Liquidation Value

ANI Pharmaceuticals (ANIP) as of March 31, 2026 presents a balance sheet dominated by intangible assets and goodwill, with a capital structure carrying $625M+ in funded debt. Under liquidation lens, recovery to equity is structurally negative on a cash liquidation basis (MFFAIS CLV -$214M), modestly positive on liquid assets only ($41M LLV), and supportive at operating liquidation value ($184M OLV), consistent with a going-concern pharmaceutical business whose value resides almost entirely in operating cash flows rather than tangible asset recovery.

Total assets of $1.42B decompose as follows: cash and equivalents $311M (100% recovery, high-quality asset), net AR $255M (90-95% recovery, ~$240M), inventory $143M (60% recovery, ~$86M), PP&E net $67M (50-70% recovery, ~$37-47M), finite-lived intangibles net $467M (0% recovery under liquidation), goodwill $62M (0% recovery), and deferred tax assets $67M (0% recovery in liquidation). Gross intangible assets of $936M with $469M accumulated amortization indicate a portfolio-heavy model—Cortrophin Gel, ILUVIEN, YUTIQ, and acquired ANDAs—all of which have zero liquidation value.

Liability stack at face value: total liabilities $860M. Funded debt includes term loan outstanding ~$309M (2024 Credit Agreement, JPMorgan) plus $316M 2.25% Convertible Senior Notes due 2029, totaling ~$625M in principal. Current liabilities of $240M include $19M current portion of long-term debt, $34M accrued royalties (face value in liquidation), $70M AP, $16M employee liabilities. Non-current liabilities include $286M long-term debt and $16M other non-current (including contingent consideration tails).

Compared to the prior filing (10-K, December 31, 2025), notable changes this quarter: (1) cash increased $26M to $311M from $286M, driven by $58M operating cash flow offset by $21M financing outflows; (2) AR increased ~$26M reflecting Q1 revenue growth; (3) inventory essentially flat at $143M; (4) convertible notes and term loan balances are modestly reduced by $4M quarterly amortization; (5) $20M treasury stock repurchases via tax withholding on restricted stock vests increased treasury stock balance; (6) a post-quarter $100M share repurchase authorization was disclosed—not reflected on the March 31 balance sheet but signals future cash deployment that would reduce the primary liquid asset.

Key liquidation headwinds: the Harmony Agreement contributed $15M upfront + ~$6.5M royalties to Q1 revenue (intangible in nature, no balance sheet asset), and royalty obligations to EyePoint (30% of U.S. net sales above $70M threshold) represent off-balance-sheet contingent liabilities through 2028. Novitium contingent consideration liability ($8.6M, Level 3) and Alimera CVRs ($1.0M) remain on balance sheet at fair value but would be settled at face value in wind-up. Filing discusses the Harmony Agreement upfront payment and royalty structure in MD&A but does not separately tag the recognized deferred revenue or receivable in XBRL.